Patients presenting to the emergency department with an acute ischemic stroke due to a large vessel occlusion eligible for thrombectomy and target mismatch on computed tomography perfusion imaging within 24 hours of onset will be assessed determine their eligibility for randomization into the trial. If the patient gives informed consent they will be randomised using a central computerised allocation process to either standard of care (no intravenous thrombolytic treatment or intravenous alteplase 0.9mg/kg) or tenecteplase before undergoing intra-arterial clot retrieval. The trial is prospective, randomised, open-label, blinded endpoint (PROBE) design.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
242
Genetically modified tissue plasminogen activator at a dose of 0.25mg/kg given as intravenous bolus over 5-10 seconds
Patients will receive standard care which may include intravenous alteplase at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.
Liverpool Hospital
Liverpool, New South Wales, Australia
John Hunter Hospital
Newcastle, New South Wales, Australia
Prince of Wales Hospital
Randwick, New South Wales, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Royal Melbourne Hospital
Melbourne, Victoria, Australia
Box Hill Hospital
Melbourne, Victoria, Australia
Modified Rankin Scale (mRS) 0-1 (no disability) or return to baseline mRS
Modified Rankin Scale (mRS) 0-1 (no disability) or return to baseline mRS (if baseline premorbid mRS =2) at 90 days
Time frame: 90 days
Early clinical improvement
Reduction in National Institutes of Health Stroke Scale (NIHSS) score of ≥8 points at 24 hours or reaching NIHSS 0-1
Time frame: 24 hours
Modified Rankin Scale (mRS) 0-2 (functional independence)
Modified Rankin Scale (mRS) 0-2 (functional independence) at 90 days
Time frame: 90 days
Substantial reperfusion at initial angiographic assessment
Proportion of patients with \>50% reperfusion of the affected vascular territory (mTICI 3b/3) on initial digital subtraction angiography prior to thrombectomy
Time frame: initial angiography within 24 hours of stroke onset
Symptomatic intracerebral hemorrhage (sICH)
sICH defined as parenchymal hematoma type 2 (PH2) - blood clot occupying \>30% of the infarcted territory with substantial mass effect
Time frame: 24 hours post-randomization
Death due to any cause
Time frame: 90 days
Modified Rankin Scale (mRS) 5-6
Poor functional outcome of death or requirement for fulltime nursing care
Time frame: 90 days
Successful reperfusion at 24 hours
Reperfusion (defined as \>90% and \>50% reduction in perfusion lesion volume)
Time frame: 24 hours
Infarct growth
Increase in the volume of irreversibly injured brain between pre-treatment and 24 hour imaging
Time frame: 24 hours
Recanalization
Change in vessel patency between pre-treatment and 24h imaging (CT or MR angiography)
Time frame: 24 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.